TAS-102 plus bevacizumab in metastatic colorectal cancer

被引：0
|
作者：
Colloca, Giuseppe A. [1 ]
Venturino, Antonella [1 ]
机构：
[1] Osped Civile Sanremo, Dept Oncol, I-18038 San Remo, Italy
来源：
LANCET ONCOLOGY | 2020年 / 21卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E226 / E226
页数：1
相关论文
共 50 条
  • [31] Phase II study of TAS-OX (TAS-102 and oxaliplatin) plus bevacizumab for late-line colorectal cancer.
    Hochster, Howard S.
    Liu, Hao
    Berim, Lyudmyla Derby
    Spencer, Kristen Renee
    Gulhati, Pat
    DiRubbo, Manda
    Cohen, Seth D.
    Lee, Patrick
    Leitner, Stuart P.
    Radovich, Delia
    Misdary, Christian
    Perez, Christian
    Datta, Sutirtha
    Gonzalez, Andrea
    Saunders, Tracie
    Boland, Patrick M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 144 - 144
  • [32] Sidedness of the primary tumor on the effect of TAS-102 for refractory metastatic colorectal cancer
    Ueda, S.
    Tsuboguchi, Y.
    Nakatani, Y.
    Tsuya, A.
    Nishina, S-I.
    Akiyoshi, K.
    Okazaki, S.
    Tokunaga, S.
    Daga, H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [33] Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
    Kawahara, Hidejiro
    Mouri, Takashi
    Ishida, Kota
    Matsumoto, Nori
    Akiba, Tadashi
    Yanaga, Katsuhiko
    ANTICANCER RESEARCH, 2018, 38 (04) : 2419 - 2422
  • [34] Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study
    Conti, Matteo
    Bolzacchini, Elena
    Luchena, Giovanna
    Bertu', Lorenza
    Tagliabue, Paola
    Aglione, Stefania
    Ardizzoia, Antonio
    Arnoffi, Jessica
    Guida, Francesco Maria
    Bertolini, Alessandro
    Pastorini, Alessandro
    Duro, Maria
    Bettega, Donato
    Roda', Giovambattista
    Artale, Salvatore
    Squizzato, Alessandro
    Giordano, Monica
    CANCERS, 2023, 15 (13)
  • [35] Neutropenia as a predictive factor in patients with metastatic colorectal cancer treated with TAS-102
    Hamauchi, S.
    Yamazaki, K.
    Masuishi, T.
    Kito, Y.
    Komori, A.
    Tsushima, T.
    Todaka, A.
    Yokota, T.
    Machida, N.
    Fukutomi, A.
    Onozawa, Y.
    Muro, K.
    Yasui, H.
    Mori, K.
    Taniguchi, H.
    ANNALS OF ONCOLOGY, 2015, 26 : 50 - 51
  • [36] Effectiveness of TAS-102 in patients with metastatic colorectal cancer in a single comprehensive cancer center
    Sales, C.
    Juliao, I.
    Rosinha, A.
    Marques, D.
    Carneiro, F.
    Faustino, C.
    Machado, M.
    Ferreira, P.
    Fragoso, M.
    Sousa, N.
    ANNALS OF ONCOLOGY, 2018, 29 : 79 - 79
  • [37] TAS-102 (Lonsurf) for the Treatment of Metastatic Colorectal Cancer. A Concise Review
    Zaniboni, Alberto
    Bertocchi, Paola
    Barni, Sandro
    Petrelli, Fausto
    Clinical Colorectal Cancer, 2016, 15 (04) : 292 - 297
  • [38] Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
    Kawahara, Hidejiro
    Yanaga, Katsuhiko
    CANCER SCIENCE, 2018, 109 : 601 - 601
  • [39] Efficacy and safety of regorafenib compared to TAS-102 for refractory metastatic colorectal cancer
    Abrahao, Ana Beatriz Kinupe
    Ko, Yoo-Joung
    Chan, Kelvin K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial
    Boland, Patrick M.
    Mukherjee, Sarbajit
    Imanirad, Iman
    Vijayvergia, Namrata
    Cohen, Seth D.
    Gupta, Medhavi
    Iyer, Renuka V.
    Bakin, Andrei
    Wang, Jianxin
    Chatley, Sarah
    Cahill, Beth
    Vadehra, Deepak
    Attwood, Kristopher
    Hochster, Howard S.
    Fountzilas, Christos
    BRITISH JOURNAL OF CANCER, 2024, 131 (08) : 1290 - 1297
12345